African human immunodeficiency virus type 1 (HIV-1)-infected children were evaluated to define the burden of Pneumocystis carinii pneumonia (PCP) and its interaction with bacterial and viral pathogens. P. carinii was identified in 101 (43.7%) of 231 episodes of pneumonia among 185 HIV-1-infected children (median age, 4.5 months; range, 1.7-27.3 months). Receipt of trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis was not associated with a significant reduction (36%; 95% confidence interval [CI], Ϫ15.4% to 64.5%) in isolation of P. carinii among children considered to have received adequate prophylaxis (37.7% of children) compared with children who had never received any prophylaxis (48.5% of children). However, deaths among children with PCP who had been taking TMP-SMX prophylaxis were markedly reduced (98.6%; 95% CI, 89.1%-99.8%) compared with children who were not taking prophylaxis. Concurrent P. carinii infection was observed in 6 of 18, 11 of 26, and 4 of 6 HIV-1-infected children who had bacteremia, a respiratory virus isolated, or Mycobacterium species isolated, respectively.
a sensitivity of 80% and specificity of 75% for diagnosis of PCP [6] . Using one or both of these techniques, P. carinii has been identified in 10%-49% of African HIV-1-infected children with severe pneumonia [6] [7] [8] . Because HIV-1-infected children account for 45% of children with severe pneumonia in South Africa [9] , it is vital to define the responsible etiologic agents for determining empirical antibiotic regimens and prioritizing the need for prophylactic measures.
Furthermore, although case reports and series have reported P. carinii coinfections that have contributed to the morbidity and mortality observed for common respiratory viral-and bacterial-associated pneumonia [10] [11] [12] [13] [14] [15] , there has been limited prospective evaluation of the frequency of this occurrence among HIV-1-infected children. The present study aimed to characterize the burden of PCP among HIV-1-infected African children with severe pneumonia and to evaluate the interaction of PCP and HIV-1 with bacterial and common respiratory virus-associated pneumonia.
MATERIALS AND METHODS

Study Site
A prospective study was conducted from March 2000 through October 2001 at Chris Hani-Baragwanath Hospital in Soweto, South Africa. In 2000, the antenatal HIV-1 seroprevalence rate at this hospital and its associated clinics was 27.8% [16] , which means that an estimated 1700 infants (7.2%) of the annual birth cohort of 24,000 have HIV-1 infection. The youngest child eligible for participation was 6 weeks of age, and the oldest was aged 3.5 years.
According to the local standard of care, neither mothers nor their children routinely receive antiretroviral drugs for the treatment of HIV-1 infection. Furthermore, trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis was recommended for all HIV-1-exposed children aged у6 weeks or as soon as the child received a diagnosis of HIV-1 infection if prophylaxis had not been previously started. Prophylaxis is continued past the age of 1 year in children with AIDS of clinical category B or C [17] . TMP-SMX is provided as a liquid formulation, and the recommended dosage for prophylaxis is 5 mg/kg of TMP combined with 20 mg/kg SMX administered daily. Prophylaxis is available for free from public hospitals as well as from primary health care clinics, and it is prescribed by either a medical doctor or nurse.
Inclusion Criteria
Subjects were part of a larger cohort among whom the efficacy of a nonavalent pneumococcal conjugate vaccine was being evaluated. Children received the standard vaccines administered in the South African expanded program for immunization, including dipththeria-tetanus-pertussis, trivalent oral polio, hepatitis B, and Haemophilus influenzae type b (Hib) conjugate vaccines, at the ages of 6, 10, and 14 weeks, and measles vaccine, at the age of 9 months.
Children were enrolled in the study if they were suspected of having HIV-1 infection and were hospitalized for severe pneumonia, which was diagnosed on the basis of the presence of the World Health Organization clinical criteria of tachypnea, which was adjusted for age as well as the presence of lower chest wall in-drawing and/or intercostals recession in malnourished children [18] . The criteria used for suspecting possible HIV-1 infection were as follows: (1) the child had previously had HIV-1 infection diagnosed, (2) the mother was known to have HIV-1 infection, or (3) the child had у3 features of the Centers for Disease Control and Prevention (CDC) category A clinical criteria for HIV-1 infection or fulfilled CDC category B or C criteria [17] .
Exclusion Criteria
Children in whom P. carinii was isolated р1 month after admission to the hospital for a previous episode of PCP were excluded from the analysis because of the possibility that they may have had residual excretion of P. carinii. Continuous asymptomatic excretion of P. carinii has been observed in twothirds of HIV-1-infected adults 1 month after successful completion of treatment for PCP [19] .
Investigations
Children were examined р18 h after admission to the hospital. The tests performed for the children enrolled in the study included the following.
Blood tests. [17] . Additional blood tests performed included complete blood cell counts (Coulter STKR), determination of the quantitative C-reactive protein level (Boehringer Mannheim Hitachi 717 Automated Analyzer), and blood culture (BacT/Alert microbial detection system; Organon Teknika) [9] .
Mycobacterium evaluation. Gastric washings for the investigation of Mycobacterium species were requested at the discretion of the attending physician and were evaluated using the Bactec method coupled with a PCR amplification test and conventional culture that used a Lowenstein-Jensen agar, as described elsewhere [20] .
Respiratory virus identification. Respiratory viral infections were evaluated using mouse monoclonal fluorescent antibody assays (Chemicon International) for respiratory syncytial virus, influenza A/B virus, parainfluenza virus types 1-3, and adenovirus, as described elsewhere [21] .
P. carinii evaluation. Induced sputum specimens were obtained for the evaluation of P. carinii [6] , followed by NPA sampling; the specimens were then mixed. This was done р72 h after admission to the hospital by a physiotherapist.
P. carinii identification was performed using a direct monoclonal antibody immunofluorescent stain (Merifluor Pneumocystis). A test result was considered to be positive if у2 typical cysts characteristic of P. carinii morphology were observed at a magnification of 100ϫ by use of dark-field microscopy [20] .
Chest radiographs. Chest radiographs were archived by digital scanning of the analogue films with use of a VXR-12 film digitizer (Vidar Systems). The chest radiographs were analyzed for the presence of alveolar consolidation (homogenous air-space infiltrates), interstitial infiltrates, and hyperinflation by a radiologist who was blinded to the child's HIV-1 infection status as well as to isolated pathogens. P. carinii: prophylaxis and treatment definitions. PCP prophylaxis was categorized as follows: (1) "adequate," if the child was reportedly receiving TMP-SMX for у1 month у3 times per week; (2) "inadequate," if the child had defaulted prophylaxis for 1-4 weeks, did not take prophylaxis regularly (!3 times per week), or had been receiving prophylaxis for !1 month; and (3) "no prophylaxis," if the child had defaulted on the use of TMP-SMX prophylaxis for 14 weeks or had never received TMP-SMX prophylaxis.
Adherence to TMP-SMX prophylaxis was determined by a review of the child's health record card, which is kept by the parent. Medication that was dispensed for the child either at a clinic or a hospital was recorded on the health record card. Furthermore, the parent was interviewed regarding whether prophylaxis was being administered. Treatment was categorized as "adequate" if it was recorded that TMP-SMX was prescribed at least at 100-200 mg of TMP-SMX per kilogram of body weight daily for 21 days or if the child was receiving an appropriate dose of TMP-SMX but died before completing treatment. Treatment was considered to be "inadequate" if a suboptimal dose was used and/or if !21 days of treatment was prescribed or if the child was treated only with trimethoprim. Children in whom only the prophylactic dose of TMP-SMX was continued were categorized as such, whereas children who did not receive a drug with activity against P. carinii were categorized as being "untreated." Only oral doses of TMP-SMX therapy were provided. All treatment decisions were at the discretion of the attending physician, including decisions that were made after investigative results became available.
Statistical Analysis
The data were analyzed using EpiInfo, version 6.04c (CDC) [22] . Continuous variables were expressed as means ‫ע‬ SDs or as medians and ranges. They were compared using Student's t test or the Kruskal Wallis H test for parametric and nonparametric results, respectively. Categorical variables were compared using Yates's corrected test or Fisher's exact test if the expected cell value was !5, and relative risks (RRs) and 95% CIs were calculated when applicable. The effectiveness of prophylaxis and the associated 95% CIs were evaluated using the unmatched case-control calculation function.
was considered to be P р .05 statistically significant.
Ethical Considerations
Ethical clearance for the study was obtained from the Committee for Research on Human Subjects at the University of the Witwatersrand, and informed written consent for inclusion into the study was obtained from the parents of the children.
RESULTS
A total of 268 pneumonia episodes were recorded among the 216 enrolled children. Thirty-seven episodes of pneumonia were excluded; 31 of these episodes occurred among 29 children who were evaluated as being HIV-1 uninfected (including 18 children with serological evidence of HIV-1 exposure, 2 children for whom HIV-1 testing was not done, and 4 children in whom P. carinii was isolated р1 month after a previous episode of PCP).
Etiology of pneumonia. P. carinii was isolated in 101 (43.7%) of 231 episodes of pneumonia, which occurred among 185 HIV-1-infected children. Two children had 2 episodes and 1 child had 3 episodes of PCP that were spaced 11 month apart. Children with PCP were younger than children in whom P. carinii was not isolated (table 1) , and PCP was more common among young infants (age, !6 months; 52.8%) than it was among older children (35.8%; table 2). Furthermore, PCP was identified in 55 (48.3%) of 114 children hospitalized for the first time with pneumonia, and it was the AIDS-defining illness in 29.7% of the children. Conversely, bacteremic pneumonia occurred more frequently among older children than among young infants, whereas respiratory viruses were isolated with similar frequency among the 2 age groups of children (table 2) .
Effectiveness of TMP-SMX prophylaxis. One-third of the children with PCP were reportedly receiving TMP-SMX prophylaxis (table 1), including 26 (26%) of 101 children who were receiving adequate prophylaxis, compared with 43 (33%) of the 130 children in whom P. carinii was not isolated and who were receiving adequate prophylaxis (
). There P p .29 was no difference observed in P. carinii isolation among those children who were recorded as having received adequate TMP-SMX prophylaxis (26 [37.7%] of 69 children) compared with those who were not receiving TMP-SMX prophylaxis (68 [48.5%] of 140 children), with the effectiveness of TMP-SMX prophylaxis against PCP being 36% (95% CI, Ϫ15.4 to 64.5;
). P p . 18 Similar results were observed when children who were reportedly receiving adequate TMP-SMX prophylaxis were compared with children who had received either no or inadequate prophylaxis (effectiveness, 29.9%; 95% CI, Ϫ24.8% to 60.6%; ), as well as when children who had received any TMP-P p .28 SMX prophylaxis were compared with children who had either defaulted prophylaxis for 11 month or had never received prophylaxis (effectiveness, 39.8%; 95% CI, Ϫ3.5% to 64.9%). The effectiveness of receipt of any TMP-SMX prophylaxis compared with no prophylaxis was 57.2% (95% CI, Ϫ25.7% to 85.2%) in young infants and 7.5% (95% CI, Ϫ96% to 56.5%) among older children. This did not differ when only children who had received adequate prophylaxis were compared with those who had not received any prophylaxis.
Clinical signs and investigations. Severe malnutrition was common (112 [48.5%] of 231 children) among the children; however, there were no clinical differences observed between children with and without PCP ( Treatment and outcome. One child who was discharged prematurely at the request of his mother was excluded from the analysis of treatment and outcome. Data regarding treatment were unavailable for an additional 3 children. Threefourths (76.7%) of the remaining 227 cases were treated empirically with appropriate PCP treatment. Six (2.8%) of 215 children who received TMP-SMX developed a skin rash, including 1 episode of erythema multiforme. Oral prednisone was provided to 70 (70.7%) of 99 children with PCP.
Children who died were younger than those who survived both for children who had PCP ( NOTE. Data are n/N (%) of children, unless otherwise indicated. The findings exclude 1 child who was discharged prematurely at the request of the mother. TMP-SMX, trimethoprim-sulfamethoxazole.
a TMP-SMX, 5-25 mg/kg for у1 month and у3 times per week. b TMP-SMX, 20-100 mg/kg per day given orally. c Includes 1 case due to Staphylococcus aureus and 2 cases due to Escherichia coli, among the children who died, and 2 cases due to Streptococcus pneumoniae and 1 case due to E. coli, among the children who survived. d Respiratory viral isolates recovered from children who survived included respiratory syncytial virus (3 children), parainfluenza virus types 1-3 (4 children), and influenza A virus (2 children). Influenza A virus was isolated from the child who died.
months];
). Among children with PCP, young infants P p .0002 had a higher mortality rate than did older children (RR, 3.1; 95% CI, 1.1-8.7; table 2), which was also true for children in whom P. carinii was not isolated (RR, 5.8; 95% CI, 2.1-16.5; table 2).
Of interest, although it was not effective for the prevention of PCP, among children in whom P. carinii was isolated, adequate TMP-SMX prophylaxis was associated with a reduced mortality rate (98.6%; 95% CI, 89.1%-99.8%; ) in com-
Ϫ5
P ! 10 parison with children who had never received any TMP-SMX prophylaxis (table 4) . This difference was not significant when analyzed independently for young infants (effectiveness, 53.3%; 95% CI, Ϫ334% to 95%) and older children (effectiveness, 82.1%; 95% CI, Ϫ89.1% to 98.3%).
Among children with PCP, adequate treatment with TMP-SMX did not affect the outcome (table 4) . Among the children with PCP who were not adequately treated with TMP-SMX were 19 children who received suboptimal doses of TMP-SMX or only TMP (in 2 cases, this was because of an adverse reaction to TMP-SMX), of whom 3 (15.8%) died, and an additional 4 children (1 of whom died) who did not receive an antimicrobial with activity against P. carinii. TMP-SMX prophylaxis among the latter 23 children included reportedly adequate prophylaxis (8 children), inadequate prophylaxis (2 children), and no prophylaxis (9 children); all of these children survived. Of the remaining 4 children, all of whom died, 3 children had not received TMP-SMX prophylaxis and 1 had received inadequate prophylaxis. As determined by in-hospital surveillance conducted during the study period, 40 (41.2%) of 97 children with PCP within died a median of 1.0 month (range, 0-12 months) after their first episode of PCP, and 29 (32.9%) of 88 children in whom P. carinii was not isolated also died ( ). P p .31 There was a trend toward increased mortality among children with bacteremia who had concurrent PCP (3 of 6) compared with children who had bacteremia and in whom P. carinii was not isolated (17 [18.5%] 
of 92;
). There was no such P p .09 difference among children with respiratory viral infections who had (1 of 10) and who did not have concurrent PCP (17 [19.3%] 
of 88;
). P p .68
DISCUSSION
The present study confirms that P. carinii is the most important cause of pneumonia in HIV-1-infected African children and highlights the ineffectiveness of the current program of TMP-SMX prophylaxis for the prevention of PCP among children who have been hospitalized for severe pneumonia. TMP-SMX prophylaxis was, however, associated with a better outcome among children who had PCP.
The mortality rate for HIV-1-infected children with PCP was similar to that in developed countries [1, 2] but was lower than that in Malawi (63%) [7] . The latter difference may be because there is easier access to treatment options, including oxygen therapy, and greater use of steroids in our region [23, 24] . Although the use of steroids did not affect mortality among children with PCP in our study, the result may have been different had mechanical ventilation been available [23, 24] . Some children with PCP survived, despite having received either inadequate treatment (16 [84%] of 19 children) or no treatment at all (3 [75%] of 4 children), which has been reported elsewhere for HIV-1-infected adults [20] . The isolation of P. carinii cysts is rare among asymptomatic immunocompromised individuals [25] , but we cannot exclude the coincidental shedding of these cysts among these children [26] . Furthermore, the isolation of P. carinii among children receiving TMP-SMX prophylaxis may not have the same significance as that for children who are not receiving prophylaxis. This may also explain the favorable outcome of PCP among those children in whom prophylaxis had seemingly failed.
Our study does have a number of limitations that may explain the high rate of TMP-SMX failures observed. Included among these limitations is that compliance with prophylaxis was determined on the basis of a record review and parental reporting but was not objectively evaluated by testing for antimicrobial presence. Furthermore, the sensitivity and specificity of the techniques used for the diagnosis of PCP may be inferior to examination of bronchoalveolar lavage specimens, which may have influenced the findings.
Despite these limitations, the low proportion of HIV-1-infected children who had been receiving TMP-SMX prophylaxis, coupled with the probability that poor compliance was the main cause of prophylaxis failure, indicate that a structural reappraisal of the current program for providing prophylaxis needs to be considered. Integration of the provision of TMP-SMX prophylaxis into the expanded program for immunization may assist in improving compliance with prophylaxis [27] and would target the age group of children at greatest risk of developing and dying of PCP. Other possible explanations for the lack of TMP-SMX prophylaxis include that those children in whom prophylaxis failed were severely immunocompromised, and, of more concern, there may have been P. carinii strains with reduced susceptibility to TMP-SMX. Infection with P. carinii strains with reduced susceptibility to sulfa-sulfone drugs has been reported elsewhere for HIV-1-infected adults who had previously received sulfa-sulfone-based prophylaxis [28] . The finding that children in whom TMP-SMX prophylaxis failed responded favorably to therapeutic doses of TMP-SMX may be in keeping with the findings for 2 individuals observed in another study [28] , who responded favorably to treatment with TMP-SMX despite being infected with P. carinii strains that had reduced susceptibility to sulfa drugs.
Our report also qualifies previous observations of the complexity of pneumonia and quantifies the magnitude of the occurrence of mixed bacterial and viral infections in children with PCP [10] . The etiology of pneumonia among HIV-1-infected children is complicated, and it is difficult to attribute morbidity and mortality to individual pathogens [9, 10, 21] . Although we were reasonably comprehensive in our evaluation for defining the etiology of pneumonia, the present study was further limited because we did not investigate for cytomegalovirus pneumonitis and other possible pathogens and because blood cultures may only have diagnosed 10%-30% of episodes of bacterial pneumonia [29] . Because we did not perform lung aspiration or lung biopsy, and because bronchoalveolar lavage specimens were not available, these limitations were unavoidable. The proportion of children who had bacteremic pneumonia (6.8%) was less than that described elsewhere from this site (14.9%) [9] -this may have been because of the introduction of Hib conjugate vaccine and because some children had possibly received the pneumococcal conjugate vaccine.
In conclusion, there are still outstanding research issues related to P. carinii in sub-Saharan Africa. These include determination of the optimal programs for providing TMP-SMX prophylaxis as well as more-effective determination of the reasons for failure of TMP-SMX prophylaxis in preventing PCP among African HIV-1-infected children.
